Choix du traitement immunosuppresseur : 2 cas cliniques et
Choix du traitement immunosuppresseur : 2 cas cliniques et
Choix du traitement immunosuppresseur : 2 cas cliniques et
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ATG (n=113) Daclizumab<br />
(n=114)<br />
p value<br />
BPAR (NEJM ) 15.0% (15%) 27.2% (25%) 0.016<br />
Steroid-resistant rejection<br />
(NEJM)<br />
Median time to rejection<br />
(days)<br />
2.7% (1.4%) 14.9% (8.0%) 0.002<br />
35 13 0.007<br />
Delayed graft function 31.5% 44.6% 0.044<br />
N° of bacterial<br />
infections/patient<br />
(mean±SD)<br />
2.5 ±1.8 1.8 ±1.2 0.014<br />
Treated CMV infection 18.6% 10.5% 0.093<br />
Graft loss 17.7% 14.0% 0.47<br />
Death 4.4% 3.5% 0.75
Change language